BioMed Nexus Daily Updates

Your essential biotech, medtech, and pharma recap — no noise, just what matters.

📌TL;DR

Lilly (LLY) reported Phase 3 ACHIEVE-4 results for Foundayo (orforglipron) on April 16 showing cardiovascular safety non-inferiority versus insulin glargine (MACE-4 HR 0.84) and a 57% lower risk of all-cause death (HR 0.43, p=0.002) in adults with type 2 diabetes at elevated cardiovascular risk. Lilly plans to submit Foundayo for type 2 diabetes under the CNPV by end of Q2 2026.
CMS shelved the BALANCE program on Tuesday after CVS and UnitedHealth balked. The Medicare GLP-1 Bridge interim program was extended through December 31, 2027. Government will fund GLP-1 coverage directly.
The FDA approved Merck's (MRK) Idvynso (doravirine/islatravir) on April 21, a week early. First non-INSTI, tenofovir-free two-drug HIV regimen to match Biktarvy in a head-to-head Phase 3 trial.
Tortugas Neuroscience debuted Tuesday with $106M in funding, four clinical-stage CNS candidates licensed from Eisai and Hansoh, and ex-Sage Therapeutics CEO Jeff Jonas at the helm.

⚡ Executive Takeaway

We should have covered ACHIEVE-4 last week and we are correcting that now. This is one of the most important Foundayo data points since the drug was approved. The trial enrolled more than 2,700 patients across 15 countries and compared Foundayo to insulin glargine in adults with type 2 diabetes who were overweight or obese with elevated cardiovascular risk. Foundayo met the primary MACE-4 non-inferiority endpoint (HR 0.84, 95% CI 0.59 to 1.20), showing a 16% relative reduction in the composite of cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain. More importantly, a pre-planned analysis showed 57% lower all-cause death with Foundayo versus insulin glargine (HR 0.43, 95% CI 0.25 to 0.75, p=0.002). At 52 weeks, Foundayo delivered superior A1C reduction (treatment difference of 0.66 percentage points) and 8.8% body weight loss versus 1.7% weight gain on insulin. These data do two things. First, they clear the cardiovascular safety bar the FDA specifically flagged in its approval letter for the obesity indication. Second, they give Lilly the filing basis for a type 2 diabetes indication, which Lilly plans to submit under the CNPV by end of Q2. A diabetes label would dramatically expand Foundayo's addressable market from roughly 40 million U.S. adults with obesity to an additional 37 million with type 2 diabetes. 👉 Read Full Analysis

🔮 What To Watch

Lilly Q1 Earnings (April 30): The most anticipated earnings report of the quarter. Expect Foundayo launch data, ACHIEVE-4 commentary, diabetes filing timeline, Kelonia/CrossBridge deal rationale, and tariff positioning.
Novo Q1 Earnings: First oral Wegovy revenue numbers. The BALANCE delay may affect long-term Medicare projections but near-term commercial momentum is the focus.
Foundayo Diabetes Filing: Lilly targets end of Q2 2026 under CNPV. If accepted, could receive an accelerated review similar to the 50-day obesity approval.
Medicare GLP-1 Bridge (July 1): Patients can access GLP-1s for weight loss through Bridge at a $50 copay. The question is whether Congress will eventually change the law to allow permanent Medicare coverage.
ASCO (May 29 to June 2): Revolution Medicines' full RASolute 302 data in a plenary session on May 31.

🔬 Clinical & Research Updates

Foundayo Meets CV Safety Bar and Shows 57% Lower Death Risk LLY
- What Happened: Lilly announced positive topline results from the Phase 3 ACHIEVE-4 trial on April 16. The trial is the largest and longest study of Foundayo in type 2 diabetes, enrolling more than 2,700 participants across 15 countries and comparing once-daily oral Foundayo to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- The Data:
  - Primary endpoint (MACE-4): Foundayo met non-inferiority vs. insulin glargine. HR 0.84 (95% CI 0.59 to 1.20). MACE-4 includes cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain.
  - All-cause mortality: 57% lower with Foundayo vs. insulin glargine. HR 0.43 (95% CI 0.25 to 0.75, nominal p=0.002). Pre-planned analysis.
  - A1C at 52 weeks: Treatment difference of 0.66 percentage points favoring Foundayo (reduction of 1.6% vs. 1.0%).
  - Body weight at 52 weeks: Foundayo patients lost 8.8% (8.1 kg). Insulin glargine patients gained 1.7%.
  - Durability: A1C and weight improvements persisted through 104 weeks.
- Executive Impact: The FDA's obesity approval letter for Foundayo specifically flagged concerns around MACE, drug-induced liver injury, delayed stomach emptying, and long-term thyroid cancer risk. ACHIEVE-4 addresses the MACE concern directly. The all-cause mortality signal (HR 0.43) is striking but needs to be interpreted carefully: this was a pre-planned exploratory analysis, not the primary endpoint, and the confidence intervals are wide (0.25 to 0.75). It is not the same as a dedicated cardiovascular outcomes trial. Still, the data package is strong enough for Lilly to file for a type 2 diabetes indication under the CNPV by end of Q2 2026. Foundayo is already being evaluated across multiple additional indications including obstructive sleep apnea, osteoarthritis, hypertension, peripheral artery disease, and stress urinary incontinence.

🏢 Corporate & Business Developments

Tortugas Neuroscience Debuts with $106M and Four Clinical CNS Programs
- Tortugas Neuroscience emerged from stealth on Tuesday with $106M in funding (seed + Series A) led by Cure Ventures, Column Group, and AN Venture Partners. CEO Jeff Jonas previously built Sage Therapeutics from startup to marketed product over a decade before stepping down in 2023. The Framingham, Massachusetts-based biotech has four clinical-stage programs licensed from Japan's Eisai and China's Hansoh, all small molecules targeting "derisked mechanisms of action" in central nervous system disorders. Jonas told BioPharma Dive the drugs offer "a rare combination of validated mechanisms and a long patent life."

📋 The Week in Review

April 16 (Wednesday): Lilly reported ACHIEVE-4 Phase 3 results. Foundayo met CV safety non-inferiority and showed 57% lower all-cause death vs. insulin glargine. Diabetes filing targeted by end of Q2 under CNPV.
April 20 (Sunday/Monday): Lilly announced Kelonia acquisition for up to $7B ($3.25B upfront). Second in vivo CAR-T deal of 2026.
April 21 (Monday): Revolution Medicines presented AACR data: daraxonrasib + chemo 58% ORR in first-line PDAC (n=40). Monotherapy 47% ORR. RM-055 next-gen catalytic inhibitor preclinical data. Full Phase 3 data secured ASCO plenary slot (May 31). Merck's Idvynso approved for HIV (week ahead of PDUFA). Tortugas Neuroscience debuted with $106M.
April 22 (Tuesday): CMS shelved BALANCE program after CVS/UnitedHealth pushback. Bridge extended through December 2027. Lilly acquired CrossBridge Bio for up to $300M (dual-payload ADC). Biogen consolidated felzartamab rights for $850M. J&J beat Q1 estimates with $15B+ in drug sales.

📅 The Week Ahead

April 28-29: Pharma Partnering US Summit (San Diego)
April 30: Lilly Q1 earnings (Foundayo launch data, ACHIEVE-4, Kelonia)
This week/next: Novo Nordisk Q1 earnings (first oral Wegovy revenue)
May 6: Royalty Pharma Q1 earnings
May 12-14: Fierce Biotech Week (Boston)
May 19: RBC Global Healthcare Conference (New York)
May 29 to June 2: ASCO Annual Meeting (Chicago)
May 31: ASCO plenary: RASolute 302 full data (RVMD)
July 1: Medicare GLP-1 Bridge program launches

👉 Read Full Analysis

🔓 BioMed Nexus Pro: Institutional Intelligence Brief

🧠 The Mortality Signal: What It Means and What It Doesn't

The 57% lower all-cause death (HR 0.43) is the headline number from ACHIEVE-4, and it requires careful interpretation.

What it means: in a trial of more than 2,700 patients, significantly fewer people died on Foundayo than on insulin glargine. The hazard ratio of 0.43 and the confidence interval (0.25 to 0.75) do not cross 1.0, meaning the result is statistically significant at the nominal level. The p-value of 0.002 is well below conventional significance thresholds.

What it does not mean: this was a pre-planned exploratory analysis, not the primary endpoint. ACHIEVE-4 was designed and powered for MACE-4 non-inferiority, not for mortality superiority. The absolute number of deaths was likely small (typical for a 2,700-patient trial over 104 weeks), which means the hazard ratio is less robust than it would be in a larger, dedicated cardiovascular outcomes trial like SELECT (semaglutide, >17,000 patients). The wide confidence interval (0.25 to 0.75) reflects this uncertainty.

The competitive implication: injectable Wegovy already carries an FDA-approved cardiovascular risk reduction claim based on the SELECT trial. Foundayo does not, and ACHIEVE-4 alone is unlikely to support one. But the data package (CV safety confirmed, mortality signal, superior A1C and weight) positions Foundayo competitively for physicians who want an oral option with a clean safety profile. Oral Wegovy does not carry a CV risk reduction claim either, so in the oral GLP-1 segment specifically, the playing field is level.

💊 The Diabetes Market Expansion

Foundayo is currently approved for obesity and overweight with comorbidities. That addressable market is roughly 40 million U.S. adults. Adding a type 2 diabetes indication opens an additional approximately 37 million Americans with T2D, many of whom are already on injectable GLP-1s or insulin.

The oral formulation is the key differentiator. Many patients with T2D resist starting injectable therapy despite clinical need. An oral daily pill with no food or water restrictions removes that barrier. If the diabetes label is approved, Foundayo would compete directly with oral Wegovy (semaglutide, which requires fasting) and Rybelsus (oral semaglutide for T2D) in the oral segment, and with the full GLP-1 injectable market in the broader T2D landscape.

Lilly's filing under CNPV by end of Q2 means a potential approval in late 2026 or early 2027. Every month the diabetes indication is delayed is revenue left on the table.

📊 Lilly Q1 Earnings Preview (April 30)

Five numbers that matter:

Foundayo Week 1 to 3 TRx: We have Week 1 data (1,390 scripts, ~2 days of capture). Lilly will provide a broader view of the launch trajectory.
Zepbound/Mounjaro revenue: Still the growth engine. How is the injectable franchise performing alongside oral Foundayo and oral Wegovy competition?
ACHIEVE-4 commentary: Will Lilly pursue a dedicated cardiovascular outcomes trial for Foundayo, or rely on ACHIEVE-4 data alone?
M&A integration: Kelonia ($7B), CrossBridge ($300M), Orna ($2.4B), Centessa ($7.8B). How is Lilly managing four simultaneous integrations?
Tariff positioning: What MFN deals has Lilly struck? What is the impact on gross margins?

🎯 Catalyst Calendar: April 2026 Forward

Date	Event	Tickers
April 30	Lilly Q1 earnings	LLY
This week/next	Novo Nordisk Q1 earnings (first oral Wegovy revenue)	NVO
April 28-29	Pharma Partnering US Summit (San Diego)	Multiple
End of Q2	Lilly Foundayo T2D filing under CNPV expected	LLY
May 6	Royalty Pharma Q1 earnings	RPRX
May 12-14	Fierce Biotech Week (Boston)	Multiple
May 19	RBC Global Healthcare Conference (New York)	Multiple
May 29 to June 2	ASCO Annual Meeting (Chicago)	Multiple
May 31	ASCO plenary: RASolute 302 full data	RVMD
Late May 2026	Commerce Section 232 report on medical devices expected	MDT, BSX, SYK, ISRG
June 2026	Takeda CEO transition (Julie Kim)	TAK
July 1	Medicare GLP-1 Bridge program launches	LLY, NVO
July 1	Foundayo Medicare Part D pricing ($50/month) targeted	LLY
July 31	Section 232 pharma tariffs effective (large companies)	Multiple
H2 2026	Lilly/Kelonia close expected	LLY
H2 2026	Beeline Medicines afimetoran Phase 2 SLE readout	Private
H2 2026	Revolution Medicines CNPV NDA filing expected	RVMD
H2 2026	Novo Nordisk Awiqli U.S. launch (first weekly insulin)	NVO
Mid-2026	Lilly retatrutide Phase 3 obesity readouts (TRIUMPH program)	LLY
Sept 19	Ultragenyx UX111 PDUFA (Sanfilippo Type A gene therapy)	RARE
Sept 29	Section 232 pharma tariffs effective (all other companies)	Multiple
Dec 31, 2027	Medicare GLP-1 Bridge program expires (extended)	LLY, NVO
End of 2026	PhRMA CEO transition	N/A